Arcturus Therapeutics Holdings Inc.
ARCT
$12.48
-$0.16-1.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.38% | -8.69% | -45.85% | -38.04% | -55.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.38% | -8.69% | -45.85% | -38.04% | -55.69% |
| Cost of Revenue | -15.74% | -1.63% | 0.10% | 21.19% | -6.22% |
| Gross Profit | 204.93% | -51.49% | -83.59% | -87.37% | -116.20% |
| SG&A Expenses | -8.66% | -0.09% | 1.39% | 3.34% | 9.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.93% | 1.21% | 2.65% | 14.77% | 21.68% |
| Operating Income | 33.47% | -22.33% | -230.93% | -302.43% | -259.58% |
| Income Before Tax | 34.82% | -190.23% | -161.04% | -185.81% | -193.37% |
| Income Tax Expenses | -117.67% | -100.16% | -90.83% | -30.48% | 50.21% |
| Earnings from Continuing Operations | 36.44% | -172.30% | -163.07% | -189.63% | -196.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.44% | -172.30% | -163.07% | -189.63% | -196.43% |
| EBIT | 33.47% | -22.33% | -230.93% | -302.43% | -259.58% |
| EBITDA | 34.51% | -22.43% | -219.93% | -284.99% | -251.64% |
| EPS Basic | 37.31% | -168.80% | -162.16% | -188.73% | -196.09% |
| Normalized Basic EPS | 35.71% | -29.06% | -189.99% | -244.50% | -233.18% |
| EPS Diluted | 37.31% | -158.58% | -164.50% | -192.83% | -199.26% |
| Normalized Diluted EPS | 35.71% | -28.28% | -193.95% | -253.66% | -238.25% |
| Average Basic Shares Outstanding | 1.40% | 1.49% | 1.26% | 0.90% | 0.65% |
| Average Diluted Shares Outstanding | 1.40% | 0.93% | 0.16% | -0.20% | -0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |